Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.52 |
| ▸ | ANPEP | P15144 | 4/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 3/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2400095 | 1.00 | MMP2 (0.52) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| SCHEMBL14117871 | 1.00 | MMP2 (0.52) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| SCHEMBL3102862 | 1.00 | MMP2 (0.52) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| Hydrochloric Acid SCHEMBL3108556 | 0.99 | MMP2 (0.51) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| SCHEMBL13623377 | 0.92 | MMP2 (0.64) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| SCHEMBL14509062 | 0.92 | MMP2 (0.50) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| SCHEMBL10084498 | 0.92 | MMP2 (0.64) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| SCHEMBL2399785 | 0.92 | MMP2 (0.64) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| SCHEMBL2399929 | 0.92 | MMP2 (0.50) | MMP2ANPEPSIGMAR1TLR2TLR1 | |
| SCHEMBL2522892 | 0.92 | MMP2 (0.50) | MMP2ANPEPSIGMAR1TLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386539-B1 | 4-Aminoproline derivatives useful as lysine mimetics | ZEALAND PHARMA AS (DK) | 2016-07-20 | — | — | EP | claimed |
| EP-1966130-B1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA AS (DK) | 2013-12-11 | — | — | EP | claimed |
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2013-08-29 | — | — | US | claimed |
| EP-2386539-A2 | Modified lysine-mimetic compounds | Zealand Pharma A/S (DK) | 2011-11-16 | — | — | EP | claimed |
| US-D647202-S1 | Bone marrow harvesting device | WARSAW ORTHOPEDIC, INC. (US) | 2011-10-18 | — | — | US | claimed |
| EP-1966130-A2 | MODIFIED LYSINE-MIMETIC COMPOUNDS | Zealand Pharma A/S (DK) | 2008-09-10 | — | — | EP | claimed |
| WO-2007078990-A2 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2007-07-12 | — | — | WO | claimed |
| US-20070149460-A1 | Modified lysine-mimetic compounds | ZEALAND PHARMA A/S (DK) | 2007-06-28 | — | — | US | claimed |
| US-9469609-B2 | Synthesis of pyrrolidine compounds | ZEALAND PHARMA A/S (DK) | 2016-10-18 | — | — | US | disclosed |
| EP-2386539-B1 | 4-Aminoproline derivatives useful as lysine mimetics | ZEALAND PHARMA AS (DK) | 2016-07-20 | — | — | EP | disclosed |
| EP-2468724-B1 | Synthesis of pyrrolidine compounds | ZEALAND PHARMA AS (DK) | 2015-11-18 | — | — | EP | disclosed |
| US-20150322007-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2015-11-12 | — | — | US | disclosed |
| US-8927590-B2 | Synthesis of pyrrolidine compounds | ZEALAND PHARMA A/S (DK) | 2015-01-06 | — | — | US | disclosed |
| EP-1966130-B1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA AS (DK) | 2013-12-11 | — | — | EP | disclosed |
| EP-2386539-A2 | Modified lysine-mimetic compounds | Zealand Pharma A/S (DK) | 2011-11-16 | — | — | EP | disclosed |
| US-D647202-S1 | Bone marrow harvesting device | WARSAW ORTHOPEDIC, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100249207-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | WYETH LLC (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1966130-A2 | MODIFIED LYSINE-MIMETIC COMPOUNDS | Zealand Pharma A/S (DK) | 2008-09-10 | — | — | EP | disclosed |
| US-20080188545-A1 | (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride monohydrate; cardiovascular disease; osteoporosis; inflammation of airway epithelium; disorders of alveolar tissue; bladder incontinence; impaired hearing; endothelial lesions | ZEALAND PHARMA A/S (DK) | 2008-08-07 | — | — | US | disclosed |
| WO-2007078990-A2 | MODIFIED LYSINE-MIMETIC COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322007-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | CPS1, DHPS, DDC | MMP2 3894/4885ANPEP 686/4885SIGMAR1 4159/4885 |
| US-20080188545-A1 | (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride monohydrate; cardiovascular disease; osteoporosis; inflammation of airway epithelium; disorders of alveolar tissue; bladder incontinence; impaired hearing; endothelial lesions | GLS, COL2A1, MYOC | MMP2 970/4885ANPEP 347/4885SIGMAR1 4393/4885 |
| US-20130225644-A1 | MODIFIED LYSINE-MIMETIC COMPOUNDS | MYLK2, KCNN2, KCNN1 | MMP2 1902/4885ANPEP 491/4885SIGMAR1 3221/4885 |
| US-20100249207-A1 | SYNTHESIS OF PYRROLIDINE COMPOUNDS | CPS1, DHPS, DDC | MMP2 3894/4885ANPEP 686/4885SIGMAR1 4159/4885 |
| US-20070149460-A1 | Modified lysine-mimetic compounds | MYLK2, KCNN2, KCNN1 | MMP2 1902/4885ANPEP 491/4885SIGMAR1 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.